By JOHN SAMARAS
Eli Lilly sells a month of 10mg Zepbound for $449 by LillyDirect, its personal pharmacy. That value holds provided that you refill inside 45 days of your final fill. Refill on day 46 and the identical field is $699. The $250 is a late payment.
Listed here are the 2 methods to purchase branded Zepbound that publish a money value. Each ship Lilly’s single-dose vials from Lilly’s personal pharmacy.
LifeMD prescribes Zepbound and fills it by the identical LillyDirect. It fees $349 to $549 for the drug the place Lilly fees $299 to $449, and payments $149 a month on high of that.
Zepbound is tirzepatide. Compounded semaglutide is a special molecule on a special value ladder. Of the 15 applications I monitor that dispense compounded GLP-1, 5 identify the pharmacy that makes it. Ten don’t.
| The place you purchase it | Printed money value | Price on high |
| Lilly direct, self-pay | $299 at 2.5mg, $399 at 5mg, $449 at 7.5mg and above | none |
| LifeMD | $349 to $549 by dose | $149 a month, $39 first month |
FDA wrote to 3 of these sellers on February 20. It instructed Strut to cease promoting its compounded medication as “Generic Zepbound, Mounjaro.” It instructed Medvi to drop “Identical energetic ingredient as Wegovy and Ozempic.” For Ivim the issue was the label. Printing “Ivim” on the vial implied Ivim had compounded the drug. It had not.
All three letters are about what the sellers wrote on a web page.
I value these applications each Monday, and the Web Archive holds what they charged earlier than I began, so the letters have a earlier than and an after. Strut marketed $149 for its starting-dose compounded semaglutide injection a month earlier than its letter and publishes $149 right now. Medvi has printed $299 for compounded semaglutide refills at each Monday examine since Could 25.
Not one of the three letters required a program to call the pharmacy that fills the order.
John Samaras is the founder and editor of GLP Chart, which tracks what each main GLP-1 program fees, checked each Monday, and publishes its methodology. No program pays to be listed or ranked.
